All In Biotech

Drug Trial Radar · NCT03945513

A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles

A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424 (Dienogest 2 mg / Ethinyl Estradiol 0.02 mg) During 13 Cycles

Last checked: Nov 20, 2026Latest source record: Nov 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,034

Actual

Start

Dec 3, 2019

Primary completion

Jun 30, 2023

Study completion Sep 8, 2023

Sponsor

Lead sponsor
Insud PharmaIndustry
Sponsor type
Industry
Collaborators
Chemo Research
First posted
May 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 13 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this trial is to demonstrate the contraceptive efficacy of LPRI424, Additional goals of the trial are to demonstrate the safety and tolerability of LPRI424.

Conditions

  • Contraception

Interventions

  • LPRI424 (dienogest/ethinylestradiol)Drug

    One LPRI424 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of pregnancies (evaluable cycles)Time frame: up to 13 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fellows Research Alliance, Inc.

    Savannah, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.